J&J divests LifeScan unit for $2.1B: 3 things to know

Mackenzie Bean - Print  | 

Johnson & Johnson will sell its LifeScan diabetes unit to the private equity firm Platinum Equity for $2.1 billion, reports CNBC.

Here are three things to know:

1. LifeScan, which produces blood glucose monitoring products, recorded $1.5 billion in net revenue in 2017.

2. J&J announced a strategic review of its diabetes businesses last year, and the company officially shut down its insulin pump unit, Animas, in October.

3. The deal is expected to close by the end of 2018.

More articles on supply chain: 
Pharmacist recommended: 30 top OTC health products of 2018
Novo Nordisk considers 3k layoffs amid turbulence in US insulin market
Bayer hikes price of 2 cancer drugs by $1k per month

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.